• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Circassia to acquire Aerocrine and Prosonix

Circassia to acquire Aerocrine and Prosonix

May 18, 2015
CenterWatch Staff

Circassia Pharmaceuticals has made an all cash offer to acquire Aerocrine, a Swedish company focused on the development and commercialization of medical diagnostic products for use in the diagnosis and management of patients with asthma, for up to $216.4 million.

Circassia also intends to acquire Prosonix, a privately-held specialty pharmaceutical company focused on the development of product candidates to treat asthma and/or chronic obstructive pulmonary disease (COPD), for an aggregate cash consideration of up to $156.6 million. Circassia proposes to raise $430.8 million, through a placing and open offer.

Steve Harris, chief executive, Circassia, said, "These proposed acquisitions and associated fundraising significantly accelerate Circassia's strategy to become a self-sustaining specialty biopharmaceutical company focused on allergy and asthma. The combined organization will give us both the capability and resources to commercialize our enlarged late-stage pipeline of potential new allergy and asthma products, once approved, and thereby generate significant shareholder value.”

"We believe Aerocrine's established commercial infrastructure, which already is targeting our core potential customers in key markets, will optimize the launch of Cat-SPIRE, which is the first of our next generation allergy immunotherapies and which remains on track to report pivotal phase III results in H1 2016,” said Harris. “Additionally, Prosonix's innovative technology gives us a portfolio of near-term products targeting asthma and other respiratory diseases, which complement our current pipeline and should enable us to further leverage Aerocrine's commercial infrastructure."

The board of directors of Aerocrine has unanimously recommended Aerocrine's shareholders to accept the offer by Circassia. The total value of the offer is a premium of 85% to Aerocrine's undisturbed closing price on April 22 and premiums of 92% and 99% to the three-month and six-month volume-weighted average prices preceding April 22. The acceptance period of the offer is expected to commence on May 19 and expire on June 11, subject to any extensions.

Upcoming Events

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

  • White House

    Trial Stakeholders Advise White House on Emergency Research Infrastructure

  • SurveywBlueBackground-360x240.png

    Stress Levels Continue to Climb in Healthcare Workforce, Survey Finds

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing